Louisiana’s abortion drug access law heightens hemorrhage risk for pregnant patients

Louisiana's 2024 law reclassified misoprostol, a critical drug for treating pregnancy-related hemorrhages, as a controlled substance, forcing hospitals to store it securely and increasing treatment delays. The law also reclassified mifepristone as a controlled substance, both of which are used in medication abortions, complicating emergency care for patients with conditions like asthma or high blood pressure.